Pharmavite’s Walsh becomes COO
NORTHRIDGE, Calif. Pharmavite on Monday announced the promotion of Mark Walsh to COO, effective immediately. Walsh has been with Pharmavite for four years as VP operations and was responsible for demand forecasting, production planning, purchasing, manufacturing, customer service and distribution for all of the company’s products.
Prior to joining Pharmavite, Walsh worked in operations for Mars, Inc.
Walsh will report to Pharmavite’s board, the company reported.
Connie Barry, president and CEO since 2005, will transition into an advisory role and will continue to serve as a member of Pharmavite’s board. Barry announced in December that she will be stepping down from that role effective Jan. 31 because of personal health issues.
Carex relaunches headache band
OAKLAND, Calif. Carex Health Brands on Friday relaunched the Thera-Med headache band, the company announced.
Thera-Med headache band is a cold pack that attaches around the head using a velcro fastener that molds to the body easily.
Micro bead gel innovation keeps the pack soft and flexible for maximum comfort with cold therapy. Featuring advanced Dual-Temp technology, the product has two sides, each made of different materials to provide either gentle cooling or maximum cold.
Public demand from migraine sufferers has prompted Carex to reintroduce the popular Headache Band with an updated design at a suggested retail price of $7.99, the company stated.
Mississippi legislators seek to reverse-switch PSE products
JACKSON, Miss. Four Mississippi legislators earlier this month added the Magnolia State as one of those states actively seeking to reverse-switch pseudoephedrine products from its current status as behind-the-pharmacy-counter to prescription-only in an effort to curb methamphetamine production.
The measures were introduced Jan. 11 by Reps. Ed Blackmon, Jr., D-Madison and Stephen Holland, D-Lee, as well as Sens. Sidney Albritton, R-District 40, and Billy Hewes, R-Harrison.
According to published reports, Marshall Fisher, director of the Mississippi Bureau of Narcotics and proponent of the legislation, noted that last year marked the first time arrests for methamphetamine possession outnumbered those for crack or cocaine by a ratio of 3-to-2.
The measures were introduced despite an offer made late last year by member companies of the Consumer Healthcare Products Association to fund an electronic logging system that could track PSE purchases across states. In November, the National Association of Drug Diversion Investigators unveiled the National Precursor Log Exchange (NPLEx), a multi-state electronic tracking program that enforces purchase limitations of the decongestant pseudoephedrine in real-time at the point of sale. The new NPLEx system has been adopted by Kentucky, Illinois and Louisiana.
“If states are wanting to make [PSE] a prescription drug, we are coming in and saying, ‘Here is a tool [being offered to] law enforcement at no cost,’” commented Charlie Cichon NADDI director, at the time of the announcement last fall.
In addition to Mississippi, California and several local jurisdictions are either considering or have passed legislation requiring a prescription for the common decongestant.